Business
Publications Confirm RVX-208 is a Unique Selective BET Bromodomain Antagonist
TSX Exchange Symbol: RVX CALGARY , Jan. 2, 2014 /CNW/ - Resverlogix Corp. (TSX: RV...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\nTSX Exchange Symbol: RVX\n\n\nCALGARY, Jan. 2, 2014 /CNW/ - Resverlogix Corp. (TSX: RVX) today\n announced that a publication titled \"RVX-208, an Inducer of ApoA-I in\n Humans, Is a BET Bromodomain Antagonist\"  was published on December 31st 2013 in the international, peer-reviewed, open-access online\n publication  PLOS ONE Journal. The publication was authored by\n Resverlogix staff in combination with collaborators from Xtal\n Biostructures Inc. in Maryland USA.\n\n\nThis publication is the third recent publication discussing the unique\n attributes of RVX-208. In October 2013 the Structural Genomics\n Consortium, in conjunction with a group of University of Oxford UK\n scientists, published a work titled \"RVX-208, an inhibitor of BET\n transcriptional regulators with selectivity for the second\n bromodomain\". This paper was a peer reviewed publication in by the\n Proceedings of the National Academy of Sciences of the United States of\n America.\n\n\n\"The Structural Genome - Oxford paper was viewed by us as an extremely\n important publication as it confirmed by an external group for the\n first time that RVX-208 was the first known selective BET inhibitor\n thus highlighting Resverlogix' technological lead in the bromodomain\n space,\" said Donald J. McCaffrey, President & CEO of Resverlogix.\n\n\nIn August 2013 a third publication in the Cell Journal, titled \"BET\n Bromodomains Mediate Transcriptional Pause Release in Heart Failure\",\n used RVX-208 as one of the BET inhibitors that confirmed the potential\n for BET inhibitors as therapeutic targets in heart failure. The authors\n of this publication were primarily from various divisions of Harvard\n Medical School.\n\n\nAbout RVX-208\n\n\nRVX-208 is a first-in-class small molecule that inhibits BET\n bromodomains. RVX-208 functions by removing atherosclerotic plaque via\n reverse cholesterol transport (RCT), the natural process through which\n atherosclerotic plaque is transported out of the arteries and removed\n from the body by the liver. RVX-208 increases production of\n Apolipoprotein A-I (ApoA-I), the key building block of functional high-density lipoprotein (HDL) particles and the type required for RCT.\n These newly produced, functional HDL particles are flat and empty and\n can efficiently remove plaque and stabilize o...